Skip to main content

Table 3 Treatment of HCC patients in NUC group and non-NUC group

From: Clinical features of hepatocellular carcinoma with hepatitis B virus among patients on Nucleos(t) ide analog therapy

 

NUC group

n = 33(%)

Non-NUC group

n = 43(%)

Liver transplantation

2(6.06%)

0(0)

Liver resection

2(6.06%)

1(2.33%)

Liver resection+TACE

2(6.06%)

2(4.65%)

TACE

17(51.52%)

2(4.65%)

Ablation

2(6.06%)

0(0)

TACE add ablation

2(6.06%)

0(0)

Sorafenib

0(0)

1(2.32%)

No treatment

6(18.18%)

37(86.04%)